Frans L. Opdam

METEOR-1: A phase I study of GSK3326595, a first-in-class protein arginine methyltransferase 5 (PRMT5) inhibitor, in advanced solid tumours

L.L. Siu, Drew Rasco, S. P. Vinay et al. · Annals of Oncology · 2019 · 133 citations · Full text

Medicine, Oncology, Pharmacology +5

The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology

David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid et al. · Nature Cancer · 2022 · 130 citations · Full text

Medicine, Biomedical Informatics, Oncology +17

Molecular Characterization of 3-Phosphoglycerate Dehydrogenase Deficiency—a Neurometabolic Disorder Associated with Reduced L-Serine Biosynthesis

Leo W. J. Klomp, Tom J. de Koning, Helga E.M. Malingré et al. · The American Journal of Human Genetics · 2000 · 111 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +15

Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer

Alison M. Schram, Kōichi Goto, Dong-Wan Kim et al. · New England Journal of Medicine · 2025 · 104 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16

DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update

Linda M. Henricks, Frans L. Opdam, J. H. Beijnen et al. · Annals of Oncology · 2017 · 93 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17